|
|
|
|
|
Jessica Imbrescia, Giulia Volpi, Silvia Lucchini, Cristian Toraci, Giorgio Facheris, Salvatore La Mattina, Navdeep Singh, Filippo Vaccher, Andrea Guerini, Michela Buglione di Monale e Bastia, Alessio Bruni and Paolo Borghetti
Background: The standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is represented by concomitant chemo-radiotherapy followed by consolidation with durvalumab that ensures a 5-year survival of 46%. However, the risk of radiother...
ver más
|
|
|
|
|